Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2026-01-21 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于山西锦波生物医药股份有限公司2025年度向特定对象发行股票的法律意见书（注册稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a specific stock issuance by Shanxi Jinbo Biopharmaceutical Co., Ltd. in 2025. It extensively discusses the legal compliance, approvals, qualifications, and conditions related to the company's targeted stock issuance. The document references relevant laws, regulatory approvals, shareholder meetings, board resolutions, and compliance with securities regulations. It is not a financial report, earnings release, or management discussion but a legal opinion related to a capital raising event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial and contains substantive content, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2026-01-21 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司向特定对象发行股票之发行保荐书（注册稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to a specific stock issuance by 山西锦波生物医药股份有限公司 to specific investors. It is issued by 中信证券股份有限公司 as the sponsor and main underwriter. The content includes detailed information about the securities issuance, the sponsor's responsibilities, legal compliance, financial data, shareholder structure, and internal review procedures. It is a formal document supporting a capital raising event through a non-public stock issuance. This type of document is a capital/financing update related to fundraising activities and changes in capital structure, not a full annual or interim report, audit report, or earnings release. It is not a mere announcement or a proxy statement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2026-01-21 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司向特定对象发行股票之上市保荐书（注册稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) for Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. regarding a specific issuance of shares to particular investors. It contains detailed information about the company, its business, financial data, risk factors, and specifics about the share issuance including pricing, quantity, and use of proceeds. The document is issued by a sponsoring institution (中信证券股份有限公司) and is related to a private placement of shares (向特定对象发行股票). This type of document is a formal underwriting and sponsorship report related to capital raising and issuance activities, not a general annual report or earnings release. It is not a simple announcement but a comprehensive filing related to a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2026-01-21 Chinese
最近2年的财务报告和审计报告及最近一期（如有）的财务报告（注册稿）
Audit Report / Information Classification · 95% confidence The document is titled “2023 年度审计报告” and contains the independent auditor’s opinion, basis for opinion, key audit matters, auditor responsibilities, and the audited financial statements (balance sheet, income statement, cash flows, equity changes, notes). It does not include management discussion and analysis, corporate narrative, or other sections typical of a full Annual Report. Therefore, it is a standalone audit report, fitting the Audit Report / Information category. FY 2023
2026-01-21 Chinese
关于拟向全资子公司增加注册资本的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's plan to increase the registered capital of its wholly-owned subsidiary. It details the investment amount, the decision-making process, and the impact on the company. There is no financial report or detailed financial statements included. The document is relatively short (1757 characters) and serves as a formal notification of a capital increase transaction. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2025-12-23 Chinese
第四届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 18th meeting of the 4th Board of Directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on specific proposals related to financing and capital increase for a subsidiary. There is no financial statement or detailed financial analysis present, nor is it a report or presentation. The content focuses on board decisions and approvals, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Therefore, the classification is MANG with high confidence.
2025-12-23 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.